Ascendis Pharma(ASND)
Focus: Ascendis Pharma is a public biotech company specializing in prodrug therapies across oncology, endocrinology, ophthalmology, neurology, and rare diseases. The company operates from Palo Alto with a focused pipeline of 14 clinical programs and one FDA-approved product (YUVIWEL).
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
60+6 this month
Growing — net +6 jobs in 30d
21 jobs added vs 15 removed. Steady team buildout.
Should You Work at Ascendis Pharma?
AI assessmentA rare disease biotech with emerging commercialization momentum and validated science, but near-term restructuring risk and limited early-career hiring opportunities make this best suited for experienced specialists in late-stage development, regulatory affairs, or medical affairs roles.
Why Work Here
- One FDA-approved product (YUVIWEL/navepegritide) launched in 2026 with seven-year orphan exclusivity in rare disease (achondroplasia), providing product commercialization experience.
Data completeness
6/9 — Partial
Company HealthStrong
Pipeline
Late-stage
5 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Growing
Growth16.4yr
First CNP therapy approved for achondroplasia (rare genetic disorder), launched April 2026 with seven-year orphan drug exclusivity and strong patent protection through 2042.
Help build intelligence for Ascendis Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.